✦ LIBER ✦

A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma

✍ Scribed by Bashir, Qaiser; Khan, Hassan; Thall, Peter F.; Liu, Ping; Shah, Nina; Kebriaei, Partow; Parmar, Simrit; Oran, Betul; Ciurea, Stefan; Nieto, Yago; Jones, Roy; Hosing, Chitra M.; Popat, Uday R.; Dinh, Yvonne T.; Rondon, Gabriela; Orlowski, Robert Z.; Shah, Jatin J.; De Lima, Marcos; Shpall, Elizabeth; Champlin, Richard; Giralt, Sergio; Qazilbash, Muzaffar H.

Book ID: 122945394
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 278 KB
Volume: 19
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2013.07.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

192Dose-reduced conditioning with fludar

192Dose-reduced conditioning with fludarabine/melphalan followed by allogeneic stem cell transplantation for patients with advanced stage II/III multiple myeloma

✍ N.M. Kröger; A. Shimoni; A. Nagler; H.G. Sayer; R. Schwerdtfeger; M. Kiehl; G. W 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Results of Phase II Clinical Trial MPD-R

Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis

✍ D. Rondelli; J.D. Goldberg; R. Marchioli; L. Isola; T.B. Shore; J.T. Prchal; A. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

A Pilot Study of T-Cell Depleted Allogen

A Pilot Study of T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation With Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics

✍ G. Koehne; H. Landau; H. Hassoun; A. Lesokhin; N. Lendvai; M. Rosenzweig; D.J. C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Relapse to prior autograft and chronic g

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ Nicolaus Kröger; Jose A. Perez-Simon; Han Myint; Hans Klingemann; Avichai Shimon 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 289 KB

A Phase I Dose-Escalation Trial of High-

A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function

✍ Abidi, Muneer H.; Agarwal, Rishi; Tageja, Nishant; Ayash, Lois; Deol, Abhinav; A 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 152 KB

Non-Myeloablative (NMA) Allogeneic Hemat

Non-Myeloablative (NMA) Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation (Bu/Flu/TBI) Conditioining: Results of a Phase II Trial

✍ Brammer, Jonathan E.; Stentz, Alex; Dibb, James; Frires, Rachel; Meyers, Gabriel 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 49 KB